Phacilitate’s inaugural special interest group, the event will draw together the cell and gene therapy sector’s manufacturing decision makers with bioprocess developers and engineers tasked with sourcing, selecting and implementing automated solutions.
Cell and Gene Therapy Catapult is one of the founding partners of this special interest group. The event will include a mixture of brainstorming sessions and activity-based networking with the aim of delivering a roadmap to cost-effective, robust and interconnected ‘vein to vein’ manufacturing and supply chain models.
This is the only event to specifically examine automation relating to product characterisation, quality testing, raw/starting materials and logistics tools and processes, in addition to bioprocessing systems.
Dr Stephen Ward, Chief Operating Officer, Cell and Gene Therapy Catapult will be delivering the session titled 'What are our future 'must haves' in terms of in-process bioanalytical tools?'